In a welcome move, Disc Medicine saw its Relative Strength Rating rise from 67 to 79 on Thursday.
How To Invest In Stocks In Both Bull And Bear Markets
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks compares to other publicly traded companies.
Decades of market research shows that the best-performing stocks often have an 80 or higher RS Rating as they launch their biggest runs. See if Disc Medicine can continue to show renewed price strength and hit that benchmark.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to form a chart pattern and break out.
The company showed 0% earnings growth last quarter, while sales growth came in at 0%. Look for the next report on or around May 19.
The company holds the No. 218 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
